3 Unpopular Stocks We Find Risky [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
for fear their firms will lose out in other business lines such as M&A advisory. At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are three stocks where the skepticism is well-placed and some better opportunities to consider. Consensus Price Target: $48.67 (-1.8% implied return) Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ:COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations. Why Are We Wary of COLL? Smaller revenue base of $757.1 million means it hasn't achieved the economies of scale that some industry juggernauts enjoy Diminishing returns on capital suggest its earlier profit pools are drying up Collegium Pharmaceutical's stock price of $49.54 implies a valuation ratio of 6.5x forward P/E. Read our free research repo
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
COLL
Earnings
- 11/6/25 - Beat
COLL
Sec Filings
- 12/17/25 - Form 144
- 12/10/25 - Form 4
- 12/9/25 - Form 4
- COLL's page on the SEC website